MedTrace Logo

Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

NCT04588194 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-10-19

No results posted yet for this study

Summary

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, romiplostim and high-dose dexamethasone.

Conditions

Interventions

DRUG

Romiplostim

Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21

DRUG

Rituximab

Rituximab 100 mg weekly days 1, 7, 14, 21

DRUG

Dexamethasone

40 mg IV/PO days 1-4

Sponsors & Collaborators

  • David Gomez Almaguer

    lead OTHER

Principal Investigators

  • David Gómez, MD · Hospital Universitario J. Eleuterio González

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-11-01
Completion
2022-11-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04588194 on ClinicalTrials.gov